Promega and Stilla announce co-marketing agreement to offer complete digital PCR workflow solution

18 May 2022

Promega Corporation – member of Atlanpole Biotherapies and leader in providing innovative solutions and technical support to the life sciences industry, and Stilla Technologies – multiplex digital PCR company , have announced a co-marketing agreement to offer a complete digital PCR solution.

The combination of Promega‘s Maxwell® automated nucleic acid extraction systems and Stilla’s Naica ® 6-color Crystal Digital PCR™ platform provides an optimized workflow for a wide range of applications in fields as diverse as cancer research, pathogen identification, infectious diseases, …

Data from the workflow combining Maxwell® extraction of circulating tumor DNA from plasma and Crystal Digital PCR™ for multiplexed detection of EGFR or PIK3C mutations was recently presented at AACR 2022.

For more details, click on this link

#AACR22 #dPCR #digitalPCR #liquidbiopsy #cancerresearch #oncology #drugdiscovery #infectiousdisease